-
1.发明公开COMPOSITIONS AND METHODS FOR REGULATING COLLAGEN AND SMOOTH MUSCLE ACTIN EXPRESSION BY SERPINE2 审中-公开组合物和方法用于调节胶原蛋白的表达及平滑肌肌动蛋白BY SERPIN2
公开(公告)号：EP2361093A2
公开(公告)日：2011-08-31
申请号：EP09810806.1
申请日：2009-11-25
发明人： BRACE, Arthur , SULLIVAN, Kathleen , FINER, Jeffrey , BOSCH, Elizabeth , BOYLE, Kathleen , WONG, Brian , PIERCE, Kristen , BHAWE, Kaumudi , DAS, Anuk , FARRELL, Francis , SIVAKUMAR, Pitchumani
CPC分类号： C07K14/811 , A61K38/57 , C07K16/38 , C07K2317/76
摘要： The invention encompasses methods and compositions for increasing or decreasing collagen 1A1 expression and/or α-smooth muscle actin expression in lung fibroblasts using SERPINE2 and antagonists of SERPINE2. The invention also encompasses methods and compositions for increasing or decreasing the formation of myofibroblasts. The invention further provides methods and compositions for treatment of lung diseases, such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.
-
公开(公告)号：EP4036118A1
公开(公告)日：2022-08-03
申请号：EP22151171.0
申请日：2014-07-31
IPC分类号： C07K16/28 , A61K31/337 , A61K31/513 , A61K33/24 , A61K39/395 , A61P1/00 , A61P43/00 , A61K39/00 , A61P35/00
摘要： The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
-
公开(公告)号：EP3708583A1
公开(公告)日：2020-09-16
申请号：EP19151147.6
申请日：2014-07-31
IPC分类号： C07K16/28 , A61K31/337 , A61K31/513 , A61K33/24 , A61K39/395 , A61P1/00 , A61P43/00 , A61K39/00 , A61P35/00
摘要： The present disclosure relates to afucosylated anti FGFR-III2b antibody constructs, their production and and their uses as pharmaceuticals. The fucosylation site is located at Asn 297 , e.g on the CH2 domain of the antibody, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
-
4.发明公开
公开(公告)号：EP3380523A1
公开(公告)日：2018-10-03
申请号：EP16816789.8
申请日：2016-11-22
发明人： PIERCE, Kristen , POWERS, Janine , PALENCIA, Servando , SIKORSKI, Robert , GHODDUSI, Majid , KRISHNAN, Kartik
IPC分类号： C07K16/28 , G01N33/574
CPC分类号： C07K16/2863 , A61K2039/505 , A61K2039/507 , A61K2039/55 , C07K16/2818 , C07K16/2896 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3069 , C07K16/3084 , C07K2317/34 , C07K2317/41 , G01N33/5091 , G01N33/57407 , G01N33/57446 , G01N33/57492 , G01N2333/71 , G01N2800/52
摘要： Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.
-
公开(公告)号：EP3027651A1
公开(公告)日：2016-06-08
申请号：EP14752705.5
申请日：2014-07-31
CPC分类号： A61K39/3955 , A61K31/337 , A61K31/513 , A61K33/24 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/2863 , C07K2317/24 , C07K2317/41 , C07K2317/732 , C07K2317/92 , A61K2300/00
摘要： The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
摘要翻译： 本发明提供了结合FGFR2IIIb的抗体，其中抗体是非岩藻糖基化的。 本发明提供包含结合FGFR2IIIb的抗体的组合物，其中组合物中至少95％的抗体是非岩藻糖基化的。 在一些实施方案中，提供了治疗癌症的方法，其包括给予无岩藻糖基化的抗FGFR2IIIb抗体。
-
公开(公告)号：EP3843767A1
公开(公告)日：2021-07-07
申请号：EP19773981.6
申请日：2019-08-28
IPC分类号： A61K38/00 , A61P35/00 , C07K14/705
-
公开(公告)号：EP3027651B1
公开(公告)日：2019-02-27
申请号：EP14752705.5
申请日：2014-07-31
IPC分类号： A61K39/395 , A61K45/06 , A61K31/337 , A61K33/24 , C07K16/28 , A61K31/513 , A61K39/00
-
8.发明公开FIBROBLAST GROWTH FACTOR RECEPTORS 1, 2, 3, AND 4 AS TARGETS FOR THERAPEUTIC INTERVENTION 审中-公开成纤维细胞生长因子受体1，2，3和4作为用于治疗性干预的靶标
公开(公告)号：EP1697420A2
公开(公告)日：2006-09-06
申请号：EP04814358.0
申请日：2004-12-17
发明人： ZENG, Changjiang , HESTIR, Kevin , PIERCE, Kristen , WILLIAMS, Lewis, T. , BOSCH, Elizabeth , MASUOKA, Lorianne , WONG, Justin, G., P. , WANG, Yan , CHU, Keting , LEE, Ernestine
CPC分类号： C07K16/2863 , C07K14/71 , G01N33/574 , G01N33/74 , G01N2333/50 , G01N2800/04 , G01N2800/065 , G01N2800/085 , G01N2800/102 , G01N2800/104 , G01N2800/105 , G01N2800/324
摘要： Isolated fibroblast growth factor receptor 1 (“FGFR1”), fibroblast growth factor receptor 2 (“FGFR2”), fibroblast growth factor receptor 3 (“FGFR3”), and fibroblast growth receptor 4 (“FGFR4”) polypeptides and polynucleotides encoding the FGFR1-4 polypeptides, respectively, are provided. Additionally, antibodies, directed to the FGFR1-4 polypeptides and polynucleotides, inclusive of all polymorphic forms and variants thereof, are described. These antibodies either specifically activate the polypeptide or specifically interfere with the activity of the polypeptide. Further provided are methods of treating diseases, such as proliferative diseases, inflammatory diseases, and metabolic disorders, and kits and compositions employing the disclosed compositions. Specifically disclosed is a method of treating tumors in a subject where an antagonist of FGFR1, FGFR2, FGFR3, and/or FGFR4 is administered to the subject.
-
公开(公告)号：EP1596813A2
公开(公告)日：2005-11-23
申请号：EP04775751.3
申请日：2004-01-30
发明人： HESTIR, Kevin , LEE, Ernestine , CHU, Keting , WANG, Yan , PIERCE, Kristen , COLLINS, Amy L., Tsui , WILLIAMS, Lewis, Thomas
IPC分类号： A61K6/00
CPC分类号： G01N33/57423 , C07K16/40 , G01N33/574 , G01N2333/70596
摘要： Modulators of phosphatidic acid phosphatase type 2C and other polypeptides, highly expressed in cancers as compared to normal tissues, are provided for treatment of proliferative disorders such as cancer. A method is provided for detecting polypeptides that are overexpressed in cancer, whereby antibodies or binding proteins that specifically recognize these molecules are contacted with a patient's bodily fluid. The method provides an early diagnosis of cancer, and can detect recurrence and metastasis following an initial diagnosis. The invention further provides methods of treating cancer with therapeutic agents directed toward these protein and peptide biomarkers.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.02 秒)
